|Description||Olanzapine (Zyprexa, Lilly) is an atypical antipsychotic agent with structural similarities to clozapine. Extensively metabolised in the liver and excreted by the kidney. It is not thought that any of the metabolites are pharmacologically active. No metabolites accumulate in plasma.|
|Indication||Therapeutic drug monitoring (TDM)|
|Interpretation||Mean plasma olanzapine half-lives are longer in elderly patients (65 y or more) (51.8 h) as compared to adults (33.8 h) and in females (36.7 h) as compared to males (32.3 h).
The limit of sensitivity of the assay is 2 µg/L (1 mL sample).
|Collection Conditions||Do NOT use gel seperator tubes
|Min. Vol||2 mL|
|Freq.||Referred to external laboratory|
|Ref. Range (Male)||20 -40|
|Ref. Range (Female)||20 -40|
|Ref. Range (Paed)|| |
|Ref. Range Notes|| 20-40|
|IP Acute TAT||1 week|
|IP Routine TAT||1 week|
|GP Acute TAT||1 week|
|GP Routine TAT||1 week|
|Turnround Comment||Robert Haddon:HutchingsAD@cardiff.ac.uk|
Originally edited by : . Review due on 17/10/2017. Published By on 17/10/2017.